We showed that the robust inhibition of the PI3K/AKT pathway can inhibit tumor progression by regulating the expression of cell cycle regulatory proteins and promote cell death in apoptosis-resistant cancers and therefore raise the potential usefulness of HBA as an excellent anticancer therapeutic candidate. This evidence concerns the gene RCC1 and neoplasm.